Catatonic Symptoms Appearing before Autonomic Symptoms Help Distinguish Neuroleptic Malignant Syndrome from Malignant Catatonia

Takayuki Komatsu¹, Tomohisa Nomura¹, Hiroki Takami¹, So Sakamoto¹, Keiko Mizuno¹, Hajime Sekii¹, Kotaro Hatta² and Manabu Sugita¹

Abstract

A 42-year-old Japanese woman with a 10-year history of schizophrenia was admitted due to a disturbance in consciousness that met the diagnostic criteria for both neuroleptic malignant syndrome (NMS) and malignant catatonia. Despite systemic supportive treatments, the catatonic symptoms preceding autonomic symptoms persisted. The symptoms improved after lorazepam administration, leading to a retrospective diagnosis of malignant catatonia. Catatonia is thought to be caused by a dysfunction of gamma-aminobutyric acid type A receptors in the cortico-cortical networks of the frontal lobes, which causes hypoactivity of the dopaminergic transmission in the subcortical areas. Identifying the catatonic symptoms preceding autonomic symptoms could aid in distinguishing malignant catatonia from NMS.

Key words: neuroleptic malignant syndrome, malignant catatonia, catatonic symptoms

(Intern Med 55: 2893-2897, 2016)
(DOI: 10.2169/internalmedicine.55.6613)

Introduction

A disturbance of consciousness is a common symptom in clinical settings. Although physiological disease should be excluded when diagnosing psychiatric diseases, it is difficult to make a definitive diagnosis when the patient is confused, particularly when the patient has a medical history of psychiatric disease.

Catatonia is a neuropsychiatric syndrome that is characterized by psychomotor abnormalities and it is observed in a variety of medical, neurological and psychiatric disorders (1). The prevalence of catatonia has been reported to range from 7-45% in various clinical settings (from 20-25% in psychiatric units) (1-6). Malignant catatonia is a rare but lethal variant of catatonia, and it primarily presents with the following symptoms in addition to the clinical features of catatonia: hyperthermia, tachycardia, tachypnea, hypertension or labile blood pressure, diaphoresis, and alternating excitement and stupor (1). Neuroleptic malignant syndrome (NMS) is a rare and fatal adverse reaction to neuroleptics in psychiatric patients, which shares many of the clinical features of malignant catatonia. Based on the existing diagnostic criteria (1, 7, 8), it is difficult to distinguish between malignant catatonia and NMS. Therefore, in this case report, we sought to identify the onset of catatonic symptoms prior to autonomic symptoms as a factor that could help to distinguish malignant catatonia from NMS.

Case Report

A 42-year-old Japanese woman with mild mental retardation and a 10-year history of schizophrenia, controlled by risperidone, diazepam, and sodium valproate was admitted to the emergency department due to a disturbance of consciousness.

On arrival, the patient had a Glasgow Coma Scale (GCS) score of 6 (E4 V1 M1), and was described as staring and mute, exhibiting an equal pupil size and normal pupil reactions. Although the patient was a GCS M1, her upper ex-

¹Department of Emergency and Critical Care Medicine, Juntendo University Nerima Hospital, Japan and ²Department of Psychiatry, Juntendo University Nerima Hospital, Japan

Received for publication September 26, 2015; Accepted for publication March 4, 2016
Correspondence to Dr. Takayuki Komatsu, komaching.1209@drive.ocn.ne.jp
tremors were also reported. Therefore, the patient fulfilled the diagnostic criteria for both NMS (muscle rigidity, fever, diaphoresis, dysphagia, tremor, altered consciousness, mutism, tachycardia, elevated blood pressure, leukocytosis and laboratory evidence of muscle injury) (7) and malignant catatonia (cataplexy, waxy flexibility, stupor, mutism, negativism, fever, tachycardia and elevated blood pressure) upon admission (1, 8). Blood tests revealed an elevated white blood cell count (16.8 x 10^9 cells/L), a myogenic enzyme with a creatine phosphokinase level of 1,538 IU/L, a lactate dehydrogenase level of 505 IU/L, and an aspartate aminotransferase level of 62 IU/L. The patient was diagnosed with pre-renal acute kidney injury (stage 2) based on an elevation of the creatinine level from 0.92 mg/dL at 12 days before admission to 2.44 mg/dL, and a urine sodium excretion level of less than 20 mmol/L. Extreme hypernatremia was also indicated by a serum sodium level of 183 mmol/L. Hematological examination also revealed abnormal coagulation and an elevation of fibrin/fibrinogen degradation product concentration (70.0 µg/mL). A blood gas analysis revealed a slight elevation in the lactate concentration (3.0 mmol/L) and normal ranges of pH and pCO2. Other hematologic indices including C-reactive protein and thyroid function were normal and the anti-nuclear antibody level showed a negative finding. Triage DOA screening (Alere Medical, Tokyo, Japan) revealed a positive result for daily benzodiazepine usage. Brain computed tomography (CT) revealed no abnormal density area or abnormal structures. Moreover, cerebrospinal fluid (CSF) examinations revealed no elevation of either the cells or the protein level with a normal glucose level. Although the patient did not exhibit tachypnea or hypoxia, an enhanced whole-body CT scan revealed bilateral pulmonary thromboembolism (PTE) and deep vein thrombosis (DVT) from the right superficial femoral vein to the popliteal vein.

We initiated crystalloid administration for volume resuscitation and heparin for PTE and DVT. We also administered ceftriaxone and acyclovir until CSF and blood culture results were negative. Based on the patient’s fulfillment of the diagnostic criteria for both NMS and malignant catatonia, we first administered dantrolene sodium hydrate to treat the NMS. Tachycardia immediately improved after volume resuscitation. Two days after admission to the intensive care unit, the abnormal blood pressure and hyperthermia also improved slightly; however, these autonomic symptoms and stupor persisted despite improvements in both dehydration and hypernatremia (see Figure) without any abnormalities on brain magnetic resonance imaging or electroencephalography. We obtained additional patient history information from the patient’s mother and a local mental clinic, and discovered that catatonic symptoms had initiated prior to the appearance of autonomic symptoms (see Table). Based on the patient history, clinical presentation, and discussion with a consultation-liaison psychiatrist, we suspected malignant catatonia or NMS superimposed on catatonia, rather than solely NMS. Therefore, we halted the administration of dantrolene sodium hydrate on the next day. At six days after admission, we subsequently administered lorazepam (1.5 mg/day) via the transluminal route. A few hours after the initiation of lorazepam treatment, the eye movement tracking improved and the verbal response to pain gradually appeared. Two days after the administration of lorazepam (8 days after admission), eye closure in response to visual stimulation appeared and we elected to administer an additional dose of lorazepam (1.5 mg/day). Nine days after admission, muscle rigidity was slightly improved and we began the concomitant administration of aripiprazole (12 mg/day) as a basic treatment for the catatonic symptoms of schizophrenia. At ten days after admission, voluntary meaningless speech and body motion appeared. Hyperthermia finally resolved on day 11 after admission. Although the patient’s symptoms had demonstrated a gradual improvement, consciousness disturbance remained at a GCS score of 7 (E4V2M1), and diaphoresis and slight tremor at the extremities persisted. Based on the patient’s clinical courses, we made a definitive retrospective diagnosis of malignant catatonia and elected to transfer the patient to a psychiatric hospital for further treatment. The patient was finally discharged from the psychiatric hospital in a stable condition after adjusting to her schizophrenia medication.

**Discussion**

Because malignant catatonia has similar clinical features to NMS, it is difficult to distinguish these diseases in patients. Fabian et al. reported statistically significant symptoms in patients with NMS, including diaphoresis (with an odds ratio of 10.011), rigor (9.550), fever (7.317), tremor (4.064), laboratory evidence of muscle injury (3.542), and leukocytosis (3.081). Fabian et al. also reported symptoms observed in catatonia, such as negativism (0.262), posturing (0.241), waxy flexibility (0.223), stupor (0.158), and stereotypy (0.122) (9). However, diaphoresis and muscle rigidity also appear in malignant catatonia, and therefore an additional index is necessary for making a differential diagnosis.

The pathophysiological mechanisms of NMS and catatonia remain unclear. However, it is hypothesized that abrupt and extensive D2 dopaminergic blockade of the anterior hypothalamus, corpus striatum, and basal ganglia corresponds to the clinical features of NMS, such as high fever, muscle rigidity, and an altered mental status, respectively (10-13). Additionally, a systematic review of NMS (14) reported that non-dopaminergic receptors, including serotonergic, adrenergic, and cholinergic receptors, may play an important role in
the pathophysiology of NMS in extrapyramidal motor functions (15), thermoregulation, muscle metabolism (16), and mental status (17). Alterations in the mental status can also be elicited by either “bottom-up” or subcortico-cortical dysfunction in gamma-aminobutyric acid type-A (GABA_A) receptor transmission in the frontal cortex secondary to any subcortical dopaminergic dysregulation (1, 16, 18). Dantrolene sodium hydrate, which inhibits calcium release from the sarcoplasmic reticulum, is therefore administered as a first-line therapy to reduce the core body temperature and peripheral muscle rigidity in NMS (13).

Conversely, catatonia may be caused by initial neurochemical abnormalities in GABA_A receptors in the cortico-cortical networks of the frontal lobes (1, 18). Dysfunction in the GABAergic-mediated balance between medial and lateral orbitofrontal cortex activity may lead to alterations in the medial prefrontal cortical pathways and thus potentially account for concomitant emotional and motor symptoms in catatonia while dysfuncison in the GABAergic balance between lateral orbitofrontal, dorsolateral prefrontal, and posterior parietal cortex networks may account for the behavioral symptoms of catatonia (18). Moreover, GABAergic dysfunction can cause secondary hypoactivity of dopaminergic transmission in the subcortical areas, specifically those connecting the orbitofrontal cortex with the striatum, and thus lead to autonomic symptoms similar to those observed in NMS. This process is referred to as “top-down” or cortico-subcortical dopaminergic dysfunction (1, 18). In accordance with the “top-down” theory, catatonic symptoms (e.g., changes in mental status) should precede the development of autonomic symptoms in malignant catatonia due to GABAergic dysfunction in the cortical areas of the frontal lobes. The first line therapy for catatonia is lorazepam, which is thought to suppress the GABA_A receptor activity, while electroconvulsive therapy (ECT) is an alternative treatment in cases refractory to the administration of lorazepam or in cases of malignant catatonia (1, 19). In the clinical setting, the most important treatment goal for both NMS and malignant catatonia is addressing the occurrence of life-threatening medical complications such as severe dehydration, hypernatremia, PTE, and DVT. However, basic advisable treatments for each disease based on the respective pathophysiological mechanisms are also required.

In this case report, it was difficult to definitively diagnose NMS on admission because the patient also exhibited various catatonic symptoms. Firstly, we hypothesized that malignant catatonia had developed from catatonia, or that NMS had been superimposed on catatonia. In either circumstance, the autonomic symptoms could be partially treated by dantrolene sodium hydrate supplemented with systemic support, and eventually lorazepam was required as a basic treatment for persisting catatonic symptoms. However, we eventually
made a retrospective diagnosis of malignant catatonia based on the clinical course of improvement of catatonic and the remaining autonomic symptoms after the administration of lorazepam. As a result, we therefore propose the initial performance of a lorazepam test (1, 20) in patients with overlapping catatonia and NMS symptoms.

The present case report demonstrates the difficulty of correctly diagnosing malignant catatonia, and suggests the utility of detecting any preceding catatonic symptoms in order to differentiate malignant catatonia from NMS. Though Walter and Jordi reported (1) the importance of events chronology in diagnosing catatonia, to our knowledge our report is the first to describe the use of vent chronology in the differentiation of malignant catatonia from NMS in a patient. Larger clinical studies should thus be performed to confirm our findings.

**Author’s disclosure of potential Conflicts of Interest (COI).**

Kotaro Hatta: Honoraria, Astellas, Dainippon-Sumitomo, Eli Lilly, Eisai, GlaxoSmithKlein, Janssen, Meiji Seika, Otsuka, Pfizer, Takeda and Tanabe-Mitsubishi.

**References**

1. Walter JA, Jordi SM. Catatonia in the emergency department. Emerg Med J 29: 863-867, 2012.
2. Gelenberg AJ. The catatonic syndrome. Lancet 1: 1339-1341, 1976.
3. Huang TL, Ree SC, Huang YC, Liu HY, Yang YY. Catatonic features: differential diagnosis and treatments at an emergency unit. Psychiatry Clin Neurosci 53: 63-66, 1999.
4. Barnes MP, Saunders M, Walls TJ, Saunders I, Kirk CA. The syndrome of Karl Ludwig Kahlbaum. J Neurol Neurosurg Psychiatry 49: 991-996, 1986.
5. Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatients population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 51: 357-362, 1990.
6. Carroll M, Taylor Am. Catatonia: a separate category for DSM-IV? Integr Psychiatry 7: 2-10, 1991.
7. American Psychiatric Association. Diagnostic and Statistical Manual of mental disorders. Fourth Edition (Text revision). American Psychiatric Association, Washington DC, 2000.
8. American Psychiatric Association. Diagnostic and Statistical Manual of mental disorders. Fifth Edition. American Psychiatric Association, Arlington, 2013.
9. Lang FU, Lang S, Becker T, Jäger M. Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psychopharmacology 232: 1-5, 2015.
10. Tseng PT, Chang YC, Chang CH, et al. Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review. Int J Psychiatri Med 49: 34-43, 2015.
11. Margetić B, Aukst-Margetić B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf 19: 429-435, 2010.
12. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin N Am 22: 389-411, 2004.
13. Adnet P, Lestavel P, Kriivosic-Horber. Neuroleptic malignant syndrome. Br J Anaesth 85: 129-135, 2000.
14. Belvederi Murr M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D 15: 45-62, 2015.

15. Ohno Y, Shimizu S, Tokudome K. Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions. Biol Pharm Bull 36: 1396-1400, 2013.

16. Guerrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 156: 169-180, 1999.

17. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Curr Drug Saf 4: 84-93, 2009.

18. Northoff G. What catatonia can tell us about “top-down modulation”: a neuropsychiatric hypothesis. Behav Brain Sci 25: 555-577, discussion 578-604, 2002.

19. Fink M, Taylor MA. Catatonia: A Clinician’s Guide to Diagnosis and Treatment. Cambridge University Press, Cambridge, 2003.

20. Dessens FM, van Paassen J, van Westerloo DJ, et al. Electroconvulsive therapy in the intensive care unit for the treatment of catatonia: a case series and review of the literature. Gen Hosp Psychiatry 38: 37-41, 2016.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).